
News|Articles|December 1, 2006
Telbivudine
Telbivudine was approved on October 25, 2006, for the treatment of chronic hepatitis B virus (HBV) in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
GLP-1s outdo aspirin in colorectal cancer prevention, study finds | ASCO Gastrointestinal Cancers Symposium
2
Stomach cancer cells make their own WNT signals to keep growing
3
Prescribing prevention: How nutrition access is reshaping affordable healthcare
4
CDC slashes list of recommended childhood vaccinations from 17 to 11
5




















































